Figure 1
(A) PFS by Mel dose for patients in CR1+CR2; (B) PFS by donor type for patients in CR1+CR2. (C) Multivariable analysis for PFS in CR1+CR2 patients (D) CD3 immune-reconstitution for MRD, MUD and TCR-haplos (medians).
(A) PFS by Mel dose for patients in CR1+CR2; (B) PFS by donor type for patients in CR1+CR2. (C) Multivariable analysis for PFS in CR1+CR2 patients (D) CD3 immune-reconstitution for MRD, MUD and TCR-haplos (medians).
